OpGen Company Executives
| OPGN Stock | USD 18.00 2.00 10.00% |
OpGen employs about 12 people. The company is managed by 12 executives with a total tenure of roughly 27 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of OpGen's management performance can provide insight into the firm performance.
| Honjian Tan Chairman CEO Chairman |
| David Lazar Chairman CEO Chairman |
OpGen |
OpGen Management Team Effectiveness
The company has return on total asset (ROA) of (0.5224) % which means that it has lost $0.5224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1492) %, meaning that it created substantial loss on money invested by shareholders. OpGen's management efficiency ratios could be used to measure how well OpGen manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of OpGen Inc is $16.38 Million. OpGen holds 3.63 pct. of its outstanding shares held by insiders and 0.26 pct. owned by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in pink sheets such as OpGen in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of OpGen, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
OpGen Workforce Comparison
OpGen Inc is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 195. OpGen holds roughly 12.0 in number of employees claiming about 6% of equities under Health Care industry.
OpGen Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OpGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on OpGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, OpGen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Lazar over a year ago Disposition of 550000 shares by David Lazar of OpGen subject to Rule 16b-3 | ||
Crovetto Mario over a year ago Acquisition by Crovetto Mario of 15000 shares of OpGen subject to Rule 16b-3 | ||
Jones Evan/ Fa over a year ago Disposition of 883 shares by Jones Evan Fa of OpGen subject to Rule 16b-3 | ||
David Lazar over a year ago Acquisition by David Lazar of 150000 shares of OpGen subject to Rule 16b-3 | ||
David Lazar over a year ago Acquisition by David Lazar of 100000 shares of OpGen subject to Rule 16b-3 | ||
Schlaeppi Yvonne over a year ago Acquisition by Schlaeppi Yvonne of 1500 shares of OpGen subject to Rule 16b-3 | ||
Versant Ventures Iii Llc over a year ago OpGen exotic insider transaction detected | ||
Oliver Schacht over a year ago Exercise or conversion by Oliver Schacht of 12469 shares of OpGen subject to Rule 16b-3 |
OpGen Notable Stakeholders
An OpGen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OpGen often face trade-offs trying to please all of them. OpGen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OpGen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Honjian Tan | CEO Chairman | Profile | |
| David Lazar | CEO Chairman | Profile | |
| Albert Weber | CFO Secretary | Profile | |
| Terrance Walker | Sr. VP of RandD | Profile | |
| Michael Farmer | VP Marketing | Profile | |
| Arne Materna | MD GmbH | Profile | |
| Derek Joesting | VP Sales | Profile | |
| Vadim Sapiro | Chief Officer | Profile | |
| Faranak Atrzadeh | Chief Officer | Profile | |
| Theo deVos | MD Genetics | Profile | |
| Johannes Bacher | Chief Officer | Profile | |
| Oliver Schacht | Executive Development | Profile |
About OpGen Management Performance
The success or failure of an entity such as OpGen Inc often depends on how effective the management is. OpGen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OpGen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OpGen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. The company was incorporated in 2001 and is headquartered in Rockville, Maryland. Opgen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 91 people.
OpGen Workforce Analysis
Traditionally, organizations such as OpGen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OpGen within its industry.OpGen Manpower Efficiency
Return on OpGen Manpower
| Revenue Per Employee | 284.9K | |
| Revenue Per Executive | 284.9K | |
| Net Loss Per Employee | 2.7M | |
| Net Loss Per Executive | 2.7M |
Other Information on Investing in OpGen Pink Sheet
OpGen financial ratios help investors to determine whether OpGen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OpGen with respect to the benefits of owning OpGen security.